KENNETT SQUARE, Pa. - Led to the gate for the first race of his career, Barbaro shied away, reluctant to get started.

Pssst! Pharmaceutical companies! Want to know a secret? One of the easiest ways to get investors jazzed up about your company is to run a clinical trial with a commercially available drug, then add naltrexone to it.

WASHINGTON, Sept. 29 (UPI) -- A new study confirms previous findings that irritable bowel syndrome is linked to fibromyalgia, a chronic pain and fatigue disorder, as well as migraines and depression.

Tired of getting that headache that seems inevitably to set in somewhere around midday every Yom Kippur? Dr. Michael Drescher, the associate chief of emergency medicine at Hartford Hospital in Connecticut, thinks he might have a cure -- Vioxx.

Lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the U.S. Food and Drug Administration's ability to evaluate and address the safety of prescription drugs after they have reached the market, says a new report from the Institute of Medicine.

Lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the U.S. Food and Drug Administration's ability to evaluate and address the safety of prescription drugs after they have reached the market, says a new report from the Institute of Medicine.

Cardiovascular disease is now a leading cause of death in rural India, according to new research published by the George Institute for International Health and the University of Queensland. The findings from a large survey conducted in Andhra Pradesh, India, highlights the rapid growth of chronic diseases and injuries in developing countries.

FRANKFORT, Ky. -- The Kentucky Mining Board took steps yesterday to allow 15 coal miners to return to work after they tested positive on company drug tests or refused to submit to testing.

IRVING, Tex. - While Dallas police yesterday concluded their investigation into Cowboys wide receiver Terrell Owens' hospitalization Tuesday night - ruling it an "accidental overdose" of prescription pain medication and not an attempted suicide - the latest T.O. controversy took a few more strange turns last night. America's Team could be in for a season-long, Texas-sized distraction with No. 81.

Alpharma Inc. (NYSE: ALO), a leading, global specialty pharmaceutical company, today announced ºpositive results from a Phase II multi-dose clinical efficacy and pharmacokinetic trial for its abuse-deterrent, extended-release opioid. [click link for full article]